Artera Achieves Nationwide Access for its ArteraAI Prostate Test with New York State License
SAN FRANCISCO--(BUSINESS WIRE)-- Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today it has received its New York laboratory permit from its Department of Health. This licensure allows Artera to offer the award-winning ArteraAI Prostate Test to one of the largest healthcare markets and makes the test available to all patients across the United States.
This milestone comes on the heels of Artera's recent announcement that its test is now updated with new insights to help higher-risk patients optimize treatment decisions. This advancement was supported by newly presented validation data, which was selected for Best of ASCO 2025.
The ArteraAI Prostate Test is the only test in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) that can both predict therapy benefit and forecast long-term outcomes in localized prostate cancer. Starting on June 4th, clinicians and patients in New York can access data-backed insights to personalize cancer treatment decisions.
'Receiving the New York lab license is a significant milestone for Artera,' said Andre Esteva, CEO and co-founder of Artera. 'Prostate cancer is one of the most common cancers, with the NY State Department of Health estimating that more than 15,000 men are diagnosed each year in New York alone. One of my founding goals was to increase access to AI-enabled precision medicine tools, and I'm proud our team has accomplished this in record time.'
New York State inspectors examined laboratory staff qualifications, equipment, facilities, safety program, record, and overall management to ensure the highest standard of care for all laboratory patients. This license follows the College of American Pathologists (CAP) accreditation Artera received in August and the State of California license in October of last year. Together, these certifications underscore Artera's commitment to quality and patient safety.
'We are thrilled that the ArteraAI Prostate Test is now available in New York,' said Himanshu Nagar, MD, Director of Genitourinary Cancer, Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center. 'This test complements existing biomarkers by integrating multimodal AI analysis of both digital pathology and clinical data, providing an additional layer of precision in risk stratification. By leveraging AI-driven insights, it enhances our ability to personalize treatment decisions, ensuring that patients receive the most appropriate therapy while minimizing unnecessary interventions.'
About Artera
Artera is a leading precision medicine company developing AI tests to personalize cancer therapy. Artera offers an AI-enabled test that is the first of its kind to provide both prognostic and predictive results for patients with localized prostate cancer: ArteraAI Prostate Test.
Artera's multimodal artificial intelligence (MMAI) biomarker test leverages a unique algorithm that assesses digital images from a patient's biopsy and their clinical data. The AI combines this information to determine their prognosis and predict whether a patient will benefit from a particular therapy and has been validated using many Phase 3 randomized trials.
Artera's laboratory is CLIA-certified and College of American Pathologists (CAP) accredited. The ArteraAI Prostate Test is clinically available through Artera's laboratory in Jacksonville, Florida, and can be ordered online at Artera.ai.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Sanofi (ENXTPA:SAN) Gains FDA Approval For Dupixent To Address Rare Skin Disease
Sanofi experienced a 4% decline over the past week despite a largely unchanged market. The recent events, including the FDA approval of Dupixent for a rare skin condition and the signing of a memorandum with the Department of Health - Abu Dhabi, signal positive developments for its collaborative efforts with Regeneron and internal growth strategies. Although these announcements are significant, they were not sufficient to counteract the broader move, which might have been influenced by other factors specific to Sanofi, such as its recent €1.5 billion notes offering aimed at supporting corporate purposes. Buy, Hold or Sell Sanofi? View our complete analysis and fair value estimate and you decide. Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. The recent developments for Sanofi, including FDA approval of Dupixent for a rare skin condition and the memorandum with the Department of Health - Abu Dhabi, highlight efforts to enhance revenue growth through expanded market reach and innovation. Despite these positive updates, Sanofi shares experienced a 4% decline over the past week, influenced by factors such as the recent €1.5 billion notes offering. Over a longer-term period, Sanofi achieved a total shareholder return of 11.29% over five years. Comparatively, over the past year, Sanofi's performance matched the French Pharmaceuticals industry, which reported a similar decline of 5.9%. In contrast, the broader French Market fared slightly better, returning 2.2%. The recent news related to Dupixent and international partnerships could potentially boost Sanofi's revenue and earnings forecasts, providing a catalyst for future growth given the innovative pipeline and market penetration opportunities. Considering the current share price of €95.9 and the analyst consensus price target of €117.7, there is potential for an 18.5% increase, according to market projections. These developments need to be weighed against existing market conditions and company fundamentals, as analysts remain divided on future earnings prospects and valuations. Click here to discover the nuances of Sanofi with our detailed analytical financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTPA:SAN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
3 hours ago
- Yahoo
Whooping cough outbreaks declared in Iqaluit, Pond Inlet
There's an outbreak of whooping cough in Iqaluit and Pond Inlet, Nunavut, according to the territory's chief public health officer. The Department of Health announced the outbreaks in a pair of news releases Saturday. It said anyone can get the respiratory disease — also known as pertussis — but that the most severe cases are in children under the age of one. Though it spreads easily from person to person, the department says it's preventable by getting vaccinated. Symptoms of whooping cough include a low fever, a cough that lasts longer than a week or is followed by an unusual "whoop" sound, vomiting after coughing and coughing that is worse at night. Anyone with these symptoms is told to stay home, avoid contact with others, and to contact their local health centre. The department says whooping cough can spread from the time someone catches it — before they start coughing — until three weeks after their symptoms have started, or until they've been taking treatment for five days. The department says whooping cough can be treated with antibiotics. They're urging people to get vaccinated against the disease, but also to curb the spread with frequent hand washing, coughing into tissues or sleeves, and not sharing food, drinks, utensils or toothbrushes. Outbreaks of whooping cough that began in Kugaruuk and Naujaat in the spring were declared over last month.
Yahoo
7 hours ago
- Yahoo
More workers are getting back together with their ex — employer, that is
Returning to work for a former employer, known as boomeranging, is back in vogue. In March, boomerang employees made up 35% of new hires, up from 31% a year earlier, according to payroll provider ADP. 'The trend of workers returning to previous employers is continuing,' Nela Richardson, ADP's chief economist, told Yahoo Finance. 'It's persistent.' For employers, 'there's a lot of uncertainty and caution in the labor market, which is showing up in the increase in boomerang hires,' she said. 'Employers are trying to get as much efficiency from their workforce as possible. And sometimes that means hiring and onboarding someone who's already familiar with the turf. They know the worker, the worker knows them.' The boomerang trend is even bigger if you count federal employees returning to their former jobs. Trump administration officials across the government are scrambling to rehire experienced workers who were forced out this spring under DOGE's staff-slashing initiative. More than 460 laid-off employees, for example, at the US Department of Health and Human Services, were reportedly sent notices last week that they are being rehired. By subscribing, you are agreeing to Yahoo's Terms and Privacy Policy Boomerang hiring comes in waves. It skyrocketed during the summer of 2020 as companies sprinted to bring back workers laid off during the pandemic shutdown that spring. Then, in 2022, millions of workers quit their jobs during the Great Resignation. In March 2022, the quit rate was 3%, with 4.5 million workers voluntarily leaving their jobs, according to the Bureau of Labor Statistics. The impetus in many cases was money. Wage growth for job switchers surged, as employers enticed workers with sweet compensation packages. Hardly anyone was looking back. Boomerang workers as a share of new hires sank to a low of 26%, per ADP. Now, far fewer people are quitting their jobs. Quits have dropped to 2% or 3.19 million workers in April. At the same time, boomerang rehiring has been steadily rising. This hiring trend has been gathering steam across virtually all industries, Richardson said, especially in media, publishing, software development, and technology. Other factors spurring the trend include a domino effect from the housing market. 'People are just less willing than they used to be to move for jobs,' Richardson said. 'With the housing market having cooled down because of higher interest rates, higher house prices, and the ability to work remotely, workers are just not as likely to move for a job. So if you're not willing to move, maybe going back to an employer that's in your local area is a stronger option than it would've been 20 years ago.' Sending a resume blindly out to job postings where you have no connection is, generally speaking, a dead-end street. Employers hire people they know, or people they know know. But if you parted a job on good terms, you have no reason not to check back in. 'The grass isn't always greener at a new company, and sometimes, you realize your previous workplace had more going for it than you remembered,' Nancy Ancowitz, a career strategist, told Yahoo Finance. 'Going back gives you the chance to bring sharper skills and a fresh perspective to familiar ground.' If getting back together appeals to you, you might join former employer alumni groups on LinkedIn and Facebook. Check out job boards and don't be bashful about contacting a former manager or ex-colleague if there's a position that catches your eye. 'Relationships matter — reaching out to former colleagues can give you the inside scoop on the team and management, and sometimes even open the door for a referral or a good word on your behalf,' Ancowitz said. When you reach out, show how you've grown. 'Spotlight the new skills, insights, and connections you've gained since you left, and explain how you're eager to use them to make an even bigger impact this time around,' she added. Be clear-eyed, however, about why you resigned. Plenty of people leave their jobs because of a bad boss, and you don't want to walk back into a toxic environment. 'You've probably heard the saying, 'people don't leave jobs, they leave managers,'' Ancowitz said. 'I see this all the time — even companies regularly ranked as top places to work can have pockets of poor management. Sometimes it's that one manager who turns your Sunday nights into a sleepless countdown to Monday.'Before making a move to reconnect, ask yourself: Will you be reporting to someone who brings out your best? 'That's often the game changer for boomerang success,' Ancowitz said. I have found that when you exit with grace, the door is always open. I have resigned from five jobs during my career, and all of my former employers and bosses became steady clients when I ran my own business. 'When I talk to HR managers around the country for firms of all sizes, they tell me that the exit conversation has changed in the last two years,' Richardson said. 'It is more like we value you, and if it doesn't work out, keep us in mind. It's not so much a goodbye, it's more of a 'see you later, let's keep in touch.' That's a big difference.' And as Ancowitz said: 'Sometimes, the sequel really is better than the original.' Kerry Hannon is a Senior Columnist at Yahoo Finance. She is a career and retirement strategist and the author of 14 books, including the forthcoming "Retirement Bites: A Gen X Guide to Securing Your Financial Future," "In Control at 50+: How to Succeed in the New World of Work" and "Never Too Old to Get Rich." Follow her on Bluesky. Sign up for the Mind Your Money newsletter Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
